State licensing boards issue warning notices on research-use-only peptides

State licensing boards for doctors, nurses and pharmacists have begun issuing formal warning notices about the clinical use of peptides, a category that includes many compounded and gray-market weight-loss and wellness products sold outside the FDA-approved drug system.^[1] Most of the notices target products labeled "research use only," but some go further, calling any non-FDA-approved peptide an "unapproved substance" and stating that giving it to a patient counts as unprofessional conduct or malpractice.^[1]

A partial list of states that have issued warnings or moved toward tighter rules includes Alabama, California, Connecticut, Louisiana, Mississippi, New Jersey, Ohio and South Carolina.^[1] In Mississippi, the boards of nursing, pharmacy and medicine issued a joint statement.^[1] South Carolina's board wrote that a licensed practitioner who buys, distributes or dispenses drugs or drug components from an unpermitted facility is "aiding and abetting unlicensed practices" and can be disciplined.^[1] Some licenses have already been suspended, and some practices have lost their licenses entirely.^[1]

The notices also close a loophole some clinics had relied on. Several boards state that handing off the actual injection or dispensing to a nurse practitioner or physician assistant does not remove the supervising physician's responsibility, and that having a patient sign a waiver does not shift legal liability either.^[1] A related legal analysis says pharmacy boards in every state require active ingredients to be pharmaceutical grade, come with a valid Certificate of Analysis, and be sourced from FDA-registered facilities — and that pharmacists who use "research use only" peptides instead are "nearly always" going to face an emergency suspension order.^[2] That same analysis notes nurses cannot legally prescribe GLP-1 or other metabolic hormone drugs, only administer them under a valid order, and that telehealth platforms face investigation when nurses evaluate or dispense these drugs without a licensed prescriber's direct order.^[2]

The crackdown is notable because it runs against a different signal from federal regulators. An FDA advisory panel recommended last month that six peptides be added to the agency's 503A Bulks List, a step that could eventually let compounding pharmacies legally prepare them.^[1] Some observers see that move as an attempt to pull the peptide market out of the gray zone rather than shut it down.^[1] State boards, by contrast, are enforcing hard against current gray-market sourcing and use in the meantime.^[1]

Why it matters for patients

For people getting semaglutide, tirzepatide or other peptides from a clinic or med spa, these warnings mean the provider giving the injection could be under active investigation or facing discipline, which can affect whether that clinic keeps operating or keeps a specific staff member on site.^[1] A signed waiver saying the patient understands the product is not FDA-approved does not protect the prescriber from board action, according to several of the notices, and it is not clear from these sources whether such waivers offer patients any legal protection either.^[1] Patients being treated by a nurse practitioner or physician assistant should know that boards say a supervising physician remains responsible for that care, which could affect how a clinic is staffed or how it responds to a complaint.^[1] The sources do not say whether patients who received treatment before these notices face any risk themselves, or whether refunds or care transitions are required when a clinic is disciplined.

What happens next

The FDA advisory panel's recommendation to add six peptides to the 503A Bulks List, made last month, would need further agency action before compounding pharmacies could legally use them, and no date for that decision is given in these sources.^[1] Legal advisors are telling pharmacists, prescribers and wholesalers to confirm state-specific rules before marketing, sourcing, prescribing or compounding peptides, and to contact counsel if they have already received an FDA warning, subpoena or board inquiry.^[1] Enforcement by FDA and consumer protection agencies against deceptive marketing and against importation of these products has also increased, according to the same report.^[1]